连续分次内可视化、软组织追踪与自动束流门控下的剂量递增磁共振图像引导腹盆腔再照射
单机构回顾性分析11例腹盆腔再照射患者,采用MRIdian直线加速器连续分次内磁共振运动管理及自动束流触发,中位再照射剂量40 Gy/6次,中位随访14个月,1年局部无进展率88.9%,1年总生存率70.0%,无≥3级急性或晚期毒性,作者认为该技术可行并可能有助于安全实现剂量递增。
要点
- 11例再照射患者中位再照射剂量40 Gy/6次,超分割方案占63.6%。
- 1年局部无进展率88.9%,1年总生存率70.0%。
- 1例(9.1%)发生急性2级毒性,无≥3级急性或晚期毒性。
核心结论
- 磁共振引导再照射看似可行,并可能有助于安全实现剂量递增。
- 需要更长的随访以更好地评估长期疗效和晚期毒性。
- 有必要对这种新型治疗策略进行前瞻性评估。
研究设计与样本
- 单机构回顾性安全性和有效性分析。
- 纳入在MRIdian直线加速器上接受腹盆腔靶区再照射的患者。
- 采用连续分次内基于磁共振的运动管理及自动束流触发,未使用基准标记。
- 共评估11例患者。
主要发现
- 既往放疗中位剂量50 Gy(范围30-58.8 Gy),25次(范围5-28次)。
- 再照射中位间隔26.8个月。
- 最常再照射部位为淋巴结转移(36.4%)和胰腺癌(27.3%)。
- 再照射中位剂量40 Gy(范围25-54 Gy),6次(范围5-36次);超分割占63.6%,高分割占36.4%。
- 3例(27.3%)采用每日在线自适应再计划。
局限性
- 原文为单机构回顾性分析。
- 样本量为11例。
- 中位随访14个月(范围6-32个月),需更长的随访以更好地评估长期疗效和晚期毒性。
- 有必要进行前瞻性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Compared with computed tomography, magnetic resonance (MR) image guidance offers significant advantages for radiation therapy (RT) that may be particularly beneficial for reirradiation (reRT). However, clinical outcomes of MR-guided reRT are not well described in the published literature. METHODS AND MATERIALS: We performed a single-institution retrospective safety and efficacy analysis of reRT patients treated on the MRIdian Linac to targets within the abdomen or pelvis using continuous intrafraction MR-based motion management with automatic beam triggering. Fiducial markers were not used. RESULTS: We evaluated 11 patients who received prior RT to a median of 50 Gy (range, 30-58.8 Gy) in 25 fractions (range, 5-28 fractions). The median interval to reRT was 26.8 months. The most frequently retreated sites were nodal metastases (36.4%) and pancreatic cancer (27.3%). The median reRT dose was 40 Gy (range, 25-54 Gy) in 6 fractions (range, 5-36 fractions); ultrahypofractionation (63.6%) was more common than hyperfractionation (36.4%). Daily on-table adaptive replanning was used for 3 patients (27.3%). With a median of 14 months' follow-up from reRT completion (range, 6-32 months), the median and 1-year freedom from local progression were 29 months and 88.9%, respectively, and the median and 1-year overall survival were 17.5 months and 70.0%, respectively. One patient (9.1%) experienced acute grade 2 toxic effects; there were no acute or late treatment-related toxic effects of grade 3 or greater. CONCLUSIONS: Magnetic resonance-guided reRT appeared to be feasible and may facilitate safe dose escalation. Additional follow-up is needed to better assess long-term efficacy and late toxic effects. Prospective evaluation of this novel treatment strategy is warranted.
引用
- Chuong MD, Bryant JM, Herrera R, et al. Dose-Escalated Magnetic Resonance Image-Guided Abdominopelvic Reirradiation With Continuous Intrafraction Visualization, Soft Tissue Tracking, and Automatic Beam Gating. Adv Radiat Oncol. 2021. PMID: 35146215. doi:10.1016/j.adro.2021.100840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。